CYTOMX Trademark

Trademark Overview

On Friday, April 21, 2017, a trademark application was filed for CYTOMX with the United States Patent and Trademark Office. The USPTO has given the CYTOMX trademark a serial number of 87978592. The federal status of this trademark filing is SECTION 8 - ACCEPTED as of Tuesday, May 13, 2025. This trademark is owned by CytomX Therapeutics, Inc.. The CYTOMX trademark is filed in the Pharmaceutical Products category with the following description:

Biological drugs for use in treating cancer [ , and autoimmunity ] ; therapeutic [ and medical diagnostic ] agents and preparations for use in therapies and diagnosis for cancer [ , and autoimmunity ] ; biochemicals, immunoglobulins and antigen-binding fragments for use in therapies [ and medical diagnosis ] for cancer [ , and autoimmunity ] ; therapeutic [ and diagnostic ] agents, preparations and substances for medical purposes for targeting application to immune system, cells [ , or genes ] ; immune modulators, immunoglobulin drug conjugates, immunotherapies and therapeutic [ and diagnostic ] agents, preparations and substances in the field of dysregulated proteolytic activity for medical purposes; immunotherapies and therapeutic [ and medical diagnostic ] agents, preparations and substances in the field of cancer, [ and autoimmunity ] for medical purposes
cytomx

General Information

Serial Number87978592
Word MarkCYTOMX
Filing DateFriday, April 21, 2017
Status701 - SECTION 8 - ACCEPTED
Status DateTuesday, May 13, 2025
Registration Number5603402
Registration DateTuesday, November 6, 2018
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 26, 2017

Trademark Statements

Goods and ServicesBiological drugs for use in treating cancer [ , and autoimmunity ] ; therapeutic [ and medical diagnostic ] agents and preparations for use in therapies and diagnosis for cancer [ , and autoimmunity ] ; biochemicals, immunoglobulins and antigen-binding fragments for use in therapies [ and medical diagnosis ] for cancer [ , and autoimmunity ] ; therapeutic [ and diagnostic ] agents, preparations and substances for medical purposes for targeting application to immune system, cells [ , or genes ] ; immune modulators, immunoglobulin drug conjugates, immunotherapies and therapeutic [ and diagnostic ] agents, preparations and substances in the field of dysregulated proteolytic activity for medical purposes; immunotherapies and therapeutic [ and medical diagnostic ] agents, preparations and substances in the field of cancer, [ and autoimmunity ] for medical purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 28, 2017
Primary Code005
First Use Anywhere DateWednesday, July 19, 2017
First Use In Commerce DateWednesday, July 19, 2017

Trademark Owner History

Party NameCytomX Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameCytomX Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameCytomX Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events

Event DateEvent Description
Monday, July 17, 2017ASSIGNED TO EXAMINER
Tuesday, April 25, 2017NEW APPLICATION ENTERED
Friday, April 28, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 24, 2017PRIORITY ACTION WRITTEN
Monday, July 24, 2017NOTIFICATION OF PRIORITY ACTION E-MAILED
Monday, July 24, 2017PRIORITY ACTION E-MAILED
Wednesday, November 8, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 8, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 9, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 14, 2017EXAMINERS AMENDMENT -WRITTEN
Tuesday, November 14, 2017NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, November 14, 2017EXAMINERS AMENDMENT E-MAILED
Tuesday, November 14, 2017EXAMINER'S AMENDMENT ENTERED
Tuesday, November 14, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 6, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 26, 2017PUBLISHED FOR OPPOSITION
Tuesday, December 26, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 6, 2018TEAS POST PUBLICATION AMENDMENT RECEIVED
Monday, August 20, 2018TEAS STATEMENT OF USE RECEIVED
Monday, August 20, 2018SOU TEAS EXTENSION RECEIVED
Monday, August 20, 2018TEAS REQUEST TO DIVIDE RECEIVED
Monday, August 20, 2018DIVISIONAL REQUEST RECEIVED
Monday, August 20, 2018SOU EXTENSION 1 FILED
Friday, February 16, 2018ASSIGNED TO PETITION STAFF
Tuesday, February 20, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, February 26, 2018POST PUBLICATION AMENDMENT - ENTERED
Monday, September 17, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 20, 2018DIVISIONAL PROCESSING COMPLETE
Monday, October 1, 2018ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, October 2, 2018NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, August 20, 2018USE AMENDMENT FILED
Thursday, September 20, 2018SOU EXTENSION 1 GRANTED
Thursday, September 20, 2018STATEMENT OF USE PROCESSING COMPLETE
Friday, September 21, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 6, 2018REGISTERED-PRINCIPAL REGISTER
Wednesday, October 16, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, October 16, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, January 21, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 21, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 30, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, January 30, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, December 23, 2024TEAS SECTION 8 RECEIVED
Tuesday, May 13, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, May 13, 2025REGISTERED - SEC. 8 (6-YR) ACCEPTED
Tuesday, May 13, 2025NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Monday, November 6, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

cytomx medical diagnostic preparations agents therapeutic cancer autoimmunity substances purposes immunotherapies